Introduction
The management of dyslipidaemia has long been a cornerstone of cardiovascular disease (CVD) prevention. While the efficacy of statins in reducing low-density lipoprotein cholesterol (LDL-C) and subsequent major adverse cardiovascular events (MACE) is well-established, the clinical community continues to debate the optimal timing for initiating therapy, particularly when elevated LDL-C is detected incidentally during routine health screenings. In many clinical scenarios, physicians and patients may opt for a ‘watchful waiting’ approach, prioritizing lifestyle modifications for several years before commencing pharmacological intervention. However, new evidence suggests that this delay may carry a significant cumulative risk.
A recent landmark study published in European Heart Journal – Quality of Care and Clinical Outcomes (2025) provides compelling epidemiological evidence regarding the consequences of delayed statin initiation. By analyzing a massive cohort of over half a million participants, researchers have quantified the risk associated with postponing treatment after the detection of high LDL-C, offering a sobering look at the impact of clinical inertia in preventive cardiology.
